Table 2.
Association between serum iCa and tCa levels and mortality in patients with AIS
| Clinical outcomes | Non-adjusted Model HR(95%CI) P value |
Model I HR(95%CI) P value |
Model II HR(95%CI) P value |
Model III HR(95%CI) P value |
||||
|---|---|---|---|---|---|---|---|---|
| 30-day mortality | ||||||||
| iCa (mmol/L) | ||||||||
| Q1 (iCa<1.07) | 2.06(1.54,2.77) | <0.001 | 2.14(1.59,2.88) | <0.001 | 1.65(1.22,2.25) | <0.001 | 1.58(1.16,2.15) | 0.004 |
| Q2 (1.07≤iCa< 1.12) | 1.83(1.35,2.48) | <0.001 | 1.84(1.36,2.49) | <0.001 | 1.64(1.21,2.23) | 0.001 | 1.55(1.13,2.11) | 0.006 |
| Q3 (1.12≤iCa< 1.17) | 1 | 1 | 1 | 1 | ||||
| Q4 (1.17≤iCa) | 1.43(1.06,1.94) | 0.020 | 1.42(1.05,1.93) | 0.023 | 1.55(1.14,2.12) | 0.005 | 1.53(1.12,2.09) | 0.008 |
| tCa (mg/dL) | ||||||||
| Q1 (tCa<7.9) | 1.14(0.87,1.50) | 0.328 | 1.21(0.93,1.59) | 0.160 | 0.94(0.71,1.24) | 0.64 | 0.85(0.63,1.14) | 0.272 |
| Q2 (7.9≤tCa<8.4) | 1.06(0.81,1.38) | 0.669 | 1.09(0.84,1.42) | 0.518 | 1.13(0.87,1.48) | 0.36 | 1.04(0.80,1.37) | 0.751 |
| Q3 (8.4≤tCa<9.0) | 1 | 1 | 1 | 1 | ||||
| Q4 (9.0≤tCa) | 0.84(0.63,1.10) | 0.206 | 0.81(0.61,1.07) | 0.132 | 0.86(0.65,1.15) | 0.31 | 0.83(0.62,1.10) | 0.195 |
| 90-day mortality | ||||||||
| iCa (mmol/L) | ||||||||
| Q1 (iCa<1.07) | 1.88(1.47,2.42) | <0.001 | 2.01(1.56,2.59) | <0.001 | 1.58(1.22,2.04) | <0.001 | 1.46(1.12,1.90) | 0.004 |
| Q2 (1.07≤iCa< 1.12) | 1.55(1.20,2.02) | 0.001 | 1.58(1.21,2.05) | <0.001 | 1.44(1.11,1.88) | 0.007 | 1.36(1.04,1.77) | 0.026 |
| Q3 (1.12≤iCa<1.17) | 1 | 1 | 1 | 1 | ||||
| Q4 (1.17≤iCa) | 1.28(0.99,1.66) | 0.059 | 1.28(0.99,1.66) | 0.063 | 1.42(1.09,1.84) | <0.01 | 1.43(1.10,1.87) | 0.008 |
| tCa (mg/dL) | ||||||||
| Q1 (tCa<7.9) | 1.12(0.88,1.42) | 0.355 | 1.20(0.94,1.53) | 0.137 | 0.91(0.71,1.17) | 0.473 | 0.83(0.64,1.08) | 0.175 |
| Q2 (7.9≤tCa<8.4) | 1.07(0.85,1.35) | 0.546 | 1.10(0.87,1.38) | 0.424 | 1.16(0.92,1.47) | 0.209 | 1.09(0.86,1.39) | 0.455 |
| Q3 (8.4≤tCa<9.0) | 1 | 1 | 1 | 1 | ||||
| Q4 (9.0≤tCa) | 0.83(0.65,1.06) | 0.133 | 0.80(0.62,1.02) | 0.071 | 0.87(0.68,1.11) | 0.260 | 0.84(0.65,1.07) | 0.16 |
| 365-day mortality | ||||||||
| iCa (mmol/L) | ||||||||
| Q1 (iCa<1.07) | 1.70(1.36,2.12) | <0.001 | 1.85(1.48,2.31) | <0.001 | 1.48(1.18,1.86) | <0.001 | 1.37(1.09,1.73) | 0.008 |
| Q2 (1.07≤iCa<1.12) | 1.45(1.15,1.82) | 0.002 | 1.48(1.17,1.86) | <0.001 | 1.36(1.08,1.72) | 0.009 | 1.30(1.02,1.63) | 0.033 |
| Q3 (1.12≤iCa<1.17) | 1 | 1 | 1 | 1 | ||||
| Q4 (1.17≤iCa) | 1.11(0.89,1.40) | 0.356 | 1.10(0.88,1.39) | 0.403 | 1.23(0.97,1.55) | 0.089 | 1.22(0.97,1.55) | 0.093 |
| tCa (mg/dL) | ||||||||
| Q1 (tCa<7.9) | 1.00(0.81,1.25) | 0.988 | 1.08(0.87,1.35) | 0.478 | 0.84(0.67,1.05) | 0.127 | 0.81(0.64,1.03) | 0.091 |
| Q2 (7.9≤tCa<8.4) | 0.97(0.79,1.20) | 0.783 | 0.98(0.80,1.21) | 0.884 | 1.05(0.85,1.29) | 0.663 | 1.03(0.83,1.28) | 0.806 |
| Q3 (8.4≤tCa<9.0) | 1 | 1 | 1 | 1 | ||||
| Q4 (9.0≤tCa) | 0.83(0.67,1.03) | 0.087 | 0.79(0.63,0.98) | 0.03 | 0.84(0.68,1.05) | 0.128 | 0.80(0.65,1.00) | 0.068 |
Non-adjusted Model: not adjusted
Mode I: adjusted for gender, race, age
Mode II: adjusted for gender, race, age, MAP, respiratory rate, heart rate, temperature, spo2, SIRS, APS III, liver disease, malignancy, renal failure, hyperlipidemia, mechanical ventilation, RRT, thrombolytic drugs and Mechanical thrombectomy
Model III: adjusted for gender, race, age, MAP, respiratory rate, heart rate, temperature, spo2, SIRS, APS III, liver disease, malignancy, renal failure, hyperlipidemia, mechanical ventilation, RRT, thrombolytic drugs, Mechanical thrombectomy, serum glucose, hemoglobin, platelet, WBC, creatinine, BUN, sodium, chloride, magnesium, bicarbonate, lactate, PH, phosphate and eGFR